COVID-19 vaccine: Potential coronavirus vaccine candidate from China shows promise in animal tests
More than 100 potential COVID-19 vaccines are in various stages of development around the world.


A vaccine is yet to be developed to prevent further spread of Covid-19, but a lot of effort and financing is going into the effort.[/caption]More than 100 potential COVID-19 vaccines are in various stages of development around the world. Among front runners currently in human trials are being developed by AstraZeneca, Pfizer, BioNtech, Johnson & Johnson, Merck, Moderna, Sanofi and China’s CanSino Biologics.As well as appearing safe and able to generate an immune response in animals, BBIBP-CorV did not appear to trigger antibodies that could boost the infection – a phenomenon known as antibody-dependent enhancement (ADE) – the researchers said, although this does not necessarily guarantee ADE won’t occur in human tests.Apart from BBIBP-CorV, Sinopharm, which has invested 1 billion yuan ($141.40 million) in vaccine projects, is testing in humans another vaccine candidate developed by its Wuhan-based unit. The two shots have been given to more than 2,000 people in clinical trials.

Stroke in young adults, silent symptoms and late diagnosis: India's growing brain health challenge
Brain tumours aren't always fatal, but delayed diagnosis can be: Experts explain the key warning signs
Spices, health and the Indian plate: Why chilli can be good for you—but moderation is still key
Organ donation: 5 myths you need to stop believing, according to a transplant specialist
Fish over meat: Why a pescatarian diet may help people with obesity live longer
